

J&J Innovative Medicine is leading where medicine is going

J&J Innovative Medicine is advancing the next era of medical innovation through our continuous R&D investments. Our net prices have continued to decline since 2016, but despite that, patients' cost exposure and access challenges are increasing because of distorted insurance benefit design.¹

Rebates and discounts to middlemen and private insurers continue to grow


Our rebates, discounts and fees reached **\$42.8 billion in 2023**.¹

The result:



Since 2016, the first year of the Transparency Report, our rebates, discounts and fees have grown each year.


Growth in rebates, discounts and fees, 2016–2023¹



Our net prices have declined by 18.6% since 2016¹

The gap between U.S. list prices, which is what we charge insurance companies, and net prices for brand-name medicines, which is after rebates and discounts provided to private insurers and other intermediaries, **grew by 45% from 2017 to 2022**.²

J&J Innovative Medicine net price change (compounded %)¹



Higher premiums and increasing cost exposure are a growing burden for families

The continuous growth in health insurance premiums is associated with limiting growth in wages for families, while patient cost exposure increases faster than the net cost of medicines that insurers and middlemen pay.^{3, 4}

By one estimate total out-of-pocket costs to patients may escalate to \$800 billion by 2026...

... equivalent to placing a

\$4,500

tax on every U.S. worker⁵



Our R&D: Developing the next generation of medicines

\$12B

J&J Innovative Medicine total investments in 2023 to research and develop treatments and cures¹

>124%

Amount spent on R&D in 2023 compared to sales and marketing¹

94

Current number of new products and indications listed for pharmaceutical development⁶

Citations

- Figure according to Johnson & Johnson internal financial accounting. Values may have been rounded.
- Adam Fein, "Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers," Drug Channels, June 2023. <https://www.drugchannels.net/2023/06/gross-to-net-bubble-update-2022-pricing.html>. Accessed July 2024.
- Kurt Hager, Ezekiel Emanuel, and Dariush Mozaffarian, "Employer-Sponsored Health Insurance Premium Cost Growth and Its Association With Earnings Inequality Among US Families," January 16, 2024. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813927>. Accessed May 2024.
- Justine Mallatt, Abe Dunn, and Lasanthi Fernando, "Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007–20," September 2024. <https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2023.01344>. Accessed May 2024.
- Kalorama Information, "Out-of-Pocket Healthcare Expenditures in the United States, 5th Edition," August 2, 2021. <https://kalorainformation.com/product/out-of-pocket-healthcare-expenditures-in-the-united-states-5th-edition/>. Accessed May 2024.
- Johnson & Johnson, "Selected Drugs in Development as of October 17, 2023," October 17, 2023. <https://www.investor.jnj.com/files/pipeline-tables/2023/10/JNJ-Pipeline-3Q2023.pdf>. Accessed January 2024.